Transcatheter Aortic Valve Implantation for Combined Aortic and Mitral Stenoses: Insights from the OCEAN-TAVI Registry
ESC Heart Failure · 2024
DOI: 10.1002/ehf2.15030 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Nahoko Kato und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Japan. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Mitral Valve Stenosis, Registries, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Edwards Lifesciences, Medtronic, Boston Scientific.
Abstract (Originalsprache)
Aims
Mitral stenosis (MS) occasionally coexists with aortic stenosis (AS). Limited data are available regarding the functional class and clinical outcomes of patients who undergo transcatheter aortic valve implantation (TAVI) for combined AS and MS. This study compared the clinical outcomes in patients with and without MS who underwent TAVI for severe AS and assessed the impact of mitral annulus calcification (MAC) severity, transmitral gradient (TMG) and mitral valve area (MVA) on outcomes in patients with combined AS and MS.
Methods
We investigated patients in the OCEAN-TAVI registry who underwent TAVI. MS was defined as an MVA ≤ 1.5 cm2 or TMG ≥ 5 mmHg. The composite of all-cause death and admission for heart failure was compared between patients with and without MS. The impact of MAC, TMG and MVA on outcomes was assessed in patients with combined AS and MS.
Results
We identified 106 patients with MS (MAC 84%; TMG 6.4 ± 2.6 mmHg; MVA 1.10 ± 0.31 cm2) and 6570 without MS as controls. The MS group was older (85 ± 5 vs. 84 ± 5 years, P = 0.033), more of women (85 vs. 67%, P < 0.01), and had a higher risk of surgery (the Society of Thoracic Surgeons Mortality Score 8.7 ± 5.1 vs. 7.6 ± 5.9, P = 0.047) than the controls. In the MS group, the New York Heart Association Functional Class was 3 or 4 in 56% of the patients at baseline and 6% at 1 year after TAVI. Thirty-day mortality (2.8% vs. 1.3%, P = 0.18) and early composite outcomes (17% vs. 15%, P = 0.56) were comparable between patients with and without MS. During a median follow-up of 2.1 years, the presence of MS was associated with a higher incidence of adverse events compared with controls (adjusted hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.34–2.51, P < 0.01), even on propensity score matched analysis (adjusted HR 1.91; 95% CI 1.14–3.22, P < 0.01). Moderate or severe MAC contributed to increased risk of adverse events in patients with MS (adjusted HR 2.89; 95% CI 1.20–6.99, P = 0.018), but TMG and MVA did not.
Conclusions
In patients undergoing TAVI for severe AS, those with moderate or severe MS experienced worse outcomes after TAVI compared with those without MS. Patients with combined AS and MS sustained symptom improvement at 1-year post-TAVI. MAC severity was a useful predictor of adverse events compared with MS haemodynamics such as TMG and MVA in patients with combined AS and MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Japan.
- Department of Cardiovascular Surgery, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
- Department of Cardiovascular surgery, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Japan.
- Department of Cardiology, Saiseikai Utsunomiya Hospital, Utsunomiya, Japan.
- Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
- Department of Cardiology, Sendai Kosei Hospital, Sendai, Japan.
ORCID-Profile: Nahoko Kato
Förderung
- Edwards Lifesciences
- Medtronic
- Boston Scientific
- Abbott
- Daiichi Sankyo
- Boston Scientific Corporation
- Abbott Medical Optics
- Daiichi Sankyo Company
Zitieren
APA
Kato, N., Tabata, M., Noguchi, M., Ito, J., Obunai, K., Watanabe, H., Yashima, F., Shirai, S., Tada, N., Naganuma, T., Yamawaki, M., Yamanaka, F., Ueno, H., Ohno, Y., Izumo, M., Nishina, H., Asami, M., Watanabe, Y., Yamamoto, M., …, & OCEAN‐TAVI investigators (2024). Transcatheter Aortic Valve Implantation for Combined Aortic and Mitral Stenoses: Insights from the OCEAN-TAVI Registry. ESC Heart Failure. https://doi.org/10.1002/ehf2.15030
Vancouver
Kato N, Tabata M, Noguchi M, Ito J, Obunai K, Watanabe H, et al. Transcatheter Aortic Valve Implantation for Combined Aortic and Mitral Stenoses: Insights from the OCEAN-TAVI Registry. ESC Heart Failure. 2024. doi:10.1002/ehf2.15030
BibTeX
@article{Kato2024,
author = {Kato, Nahoko and Tabata, Minoru and Noguchi, Masahiko and Ito, Joji and Obunai, Kotaro and Watanabe, Hiroyuki and Yashima, Fumiaki and Shirai, Shinichi and Tada, Norio and Naganuma, Toru and Yamawaki, Masahiro and Yamanaka, Futoshi and Ueno, Hiroshi and Ohno, Yohei and Izumo, Masaki and Nishina, Hidetaka and Asami, Masahiko and Watanabe, Yusuke and Yamamoto, Masanori and Otsuka, Toshiaki and Hayashida, Kentaro and OCEAN‐TAVI investigators, OCEAN‐TAVI investigators},
title = {Transcatheter Aortic Valve Implantation for Combined Aortic and Mitral Stenoses: Insights from the OCEAN-TAVI Registry},
journal = {ESC Heart Failure},
year = {2024},
doi = {10.1002/ehf2.15030}
}
EUVIMED